A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
Phase 3
Withdrawn
- Conditions
- Intravenous Steroid-Refractory Ulcerative Colitis
- Registration Number
- NCT00502294
- Lead Sponsor
- Facet Biotech
- Brief Summary
To compare the efficacy of visilizumab at 5 mcg/kg/day administered intravenously (IV) on Days 1 and 2 to placebo in subjects with IVSR-UC.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- Males and females, 18 years of age or older.
- Diagnosis of UC verified by endoscopy within 60 months prior to consent.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method